Skip to main content
SpringerLink
Log in

Mapping the Progress of Alzheimer’s and Parkinson’s Disease

  • Book
  • © 2002

Overview

Editors:
  1. Yoshikuni Mizuno

    1. Juntendo University School of Medicine, Tokyo, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Abraham Fisher

    1. Israel Institute for Biological Research, Ness-Ziona, Israel

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Israel Hanin

    1. Stritch School of Medicine, Loyola University Chicago, Maywood, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Advances in Behavioral Biology (ABBI, volume 51)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (92 chapters)

  1. Progress in Alzheimer’s Disease

    1. Animal Models of Alzheimer’s Disease

      1. Neuropeptide Expression in Animal Disease Models
        • Tomas Hökfelt, Margarita Diez, Tiejun Shi, Jari Koistinaho, Dora Games, Karen Kahn et al.
        Pages 117-120
      2. Role of Inducible Nitric Oxide Synthase in β-Amyloid-Induced Brain Dysfunction in Rats
        • Kiyofumi Yamada, Manh Hung Tran, Hyoung-Chun Kim, Toshitaka Nabeshima
        Pages 121-126
      3. Amyloid Pathology and Cholinergic Networks in Transgenic Models of Alzheimer’s Disease
        • A. Claudio Cuello
        Pages 127-132
      4. Mechanism of Neuronal Death in Alzheimer’s Disease
        • Michael C. Irizarry
        Pages 133-138
      5. Interactions of Beta-Amyloid with the Formation of Neurofibrillary Tangles in Transgenic Mice
        • Jürgen Götz, Feng Chen, Roger M. Nitsch
        Pages 139-144

    2. Glycosaminoglycans (GAGs) in Alzheimer’s Disease

      1. Historical Overview of Glycosaminoglycans (GAGs) and their Potential Value in the Treatment of Alzheimer’s Disease
        • U. Cornelli, I. Hanin, S. Lorens, J. Fareed, J. Lee, R. Mervis et al.
        Pages 145-155
      2. Glycosaminoglycans and Glycomimetics: Potential Role in the Management of Alzheimer’s Disease
        • Qing Ma, Jawed Fareed, Bertalan Dudas, Umberto Cornelli, Stanley Lorens, John Lee et al.
        Pages 157-163
      3. Low Molecular Weight Glycosaminoglycan Blockade of Beta Amyloid (25–35) Induced Neuropathology
        • M. Walzer, S. Lorens, M. Hejna, J. Fareed, R. Mervis, I. Hanin et al.
        Pages 165-170
      4. C3, A Promising Ultra Low Molecular Weight Glycosaminoglycan for the Treatment of Alzheimer’s Disease
        • Israel Hanin, Bertalan Dudas, Ronald F. Mervis, Umberto Cornelli, John M. Lee, Stanley A. Lorens et al.
        Pages 171-176

    3. Clinical Evaluation of Alzheimer’s Disease

      1. Mild Cognitive Impairment
        • Vesna Jelic, Bengt Winblad
        Pages 177-182
      2. Functional Activation Studies in Alzheimer Patients and Strategies in Drug Evaluation
        • Agneta Nordberg
        Pages 183-186

    4. Progress in the Treatment of Alzheimer’s Disease

      1. Structural and Functional Correlates of Human Acetylcholinesterase Mutants for Evaluating Alzheimer’s Disease Treatments
        • Avigdor Shafferman, Dov Barak, Arie Ordentlich, Naomi Ariel, Chanoch Kronman, Dana Kaplan et al.
        Pages 187-192
      2. The New Generation of Acetylcholinesterase Inhibitors
        • Hachiro Sugimoto, Yoichi Iimura, Yoshiharu Yamanishi
        Pages 193-198
      3. TV3326, A Novel Cholinesterase and Mao Inhibitor
        • Marta Weinstock, Tatyana Poltyrev, Corina Bejar, Yotam Sagi, Moussa B. H. Youdim
        Pages 199-204

    5. Novel Drug Treatment of Alzheimer’s Disease: Beyond Cholinesterase Inhibitors

      1. M1 Muscarinic Agonists as a Therapeutic Strategy in Alzheimer’s Disease
        • Abraham Fisher, Zipora Pittel, Rachel Haring, Rachel Brandeis, Nira Bar-Ner, Hagar Sonego et al.
        Pages 205-210
      2. Phenserine Regulates Translation of ß—Amyloid Precursor Protein Message
        • D. K. Lahiri, T. Utsuki, K. T. Y. Shaw, Y.-W. Ge, K. Sambamurti, P. S. Eder et al.
        Pages 211-215
      3. The Forkhead Family of Transcription Factors are Targets of AKT in IGF-1 Mediated Survival in Neuronal Cells
        • Wen-Hua Zheng, Satyabrata Kar, Remi Quirion
        Pages 217-222

    6. New Treatment on the Horizon in Alzheimer’s Disease

      1. Development of Anti-Dementia Drugs for Alzheimer’s Disease: Present And Future
        • Toshitaka Nabeshima, Kiyofumi Yamada
        Pages 223-228
      2. Human Neural Stem Cell Transplantation Improves Cognitive Function of Aged Brain
        • Kiminobu Sugaya, Tingyu Qu, Hojoong M. Kim, Christopher L. Brannen
        Pages 229-234
      3. BiP/GRP78-Induced Microglial Activation and Increase of Aß Clearance
        • Yoshihisa Kitamura, Jun-ichi Kakimura, Takashi Taniguchi, Shun Shimohama, Peter J. Gebicke-Haerter
        Pages 235-238
Back to top

Keywords

About this book

1h The 5 International Conference on the Progress in Alzheimer's Disease and Parkinson's 51 1 Disease took place from March 31 to April 5 \ 2001 in Kroto, Japan. This international 1 conference was organized as a joint Congress with the 9 International Catecholamine Symposium. A total of 1258 clinicians and researchers participated in this joint congress 1h from 38 countries in the world. This book represents the proceedings of the 5 Conference on Alzheimer's and Parkinson's disease. The International Conference on the Progress in Alzheimer's and Parkinson's disease was first launched by Professor Abraham Fisher of Israel and Professor Israel Hanin of USA. The first conference was held in Eilat, Israel in 1985. The second conference was organized in Kyoto, Japan in 1989; the third one in Chicago, USA, in 1993, and the fourth one in Eilat, Israel in 1997. The International Catecholamine Symposium (ICS) is an international meeting devoted to the development of basic as well as clinical research on catecholamines. The first Catecholamine Symposium was held in Bethesda, USA in 1958. Since then this symposium has occurred every 5 years. Professor Toshiharu Nagatsu was appointed as 1h the president of the 9 International Catecholamine Symposium, which was to be held in 200 I also in Japan. Therefore, we decided to organize a joint congress of the two meetings, because there is much overlap in research between Alzheimer's disease, Parkinson's disease, and catecholamines. We thank Professor Nagatsu very much for agreeing to organizing this joint congress.

Editors and Affiliations

  • Juntendo University School of Medicine, Tokyo, Japan

    Yoshikuni Mizuno

  • Israel Institute for Biological Research, Ness-Ziona, Israel

    Abraham Fisher

  • Stritch School of Medicine, Loyola University Chicago, Maywood, USA

    Israel Hanin

Bibliographic Information

  • Book Title: Mapping the Progress of Alzheimer’s and Parkinson’s Disease

  • Editors: Yoshikuni Mizuno, Abraham Fisher, Israel Hanin

  • Series Title: Advances in Behavioral Biology

  • DOI: https://doi.org/10.1007/978-0-306-47593-1

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2002

  • Hardcover ISBN: 978-0-306-46763-9Published: 31 March 2002

  • Softcover ISBN: 978-1-4757-0973-5Published: 26 November 2012

  • eBook ISBN: 978-0-306-47593-1Published: 31 March 2002

  • Series ISSN: 0099-6246

  • Edition Number: 1

  • Number of Pages: XXII, 566

  • Topics: Neurosciences, Pathology, Pharmacology/Toxicology, Psychiatry, Geriatrics/Gerontology

Publish with us

Policies and ethics

Back to top

Search

Navigation